Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new ...

Hello and welcome to the Geron fourth quarter and full year 2024 earnings call. All lines have been placed on mute to prevent ...

Geron Corp (GERN) reports a robust cash reserve and key FDA approval for Rytelo, but faces flat revenue trends and leadership changes in its commercial strategy.

B. Riley dropped their FY2025 earnings per share (EPS) estimates for shares of Geron in a research report issued to clients ...

Geron ended 2024 with a strong cash position and reported that revenues for the third and fourth quarters exceeded expectations. The company's net product revenue for RYTELO reached $47.5 million in ...

FOSTER CITY, Calif. (AP) — FOSTER CITY, Calif. (AP) — Geron Corp. (GERN) on Wednesday reported a loss of $25.4 million in its fourth quarter. The Foster City, California-based company said it had a ...

We recently published a list of 10 Best Nasdaq Stocks Under $5 to Buy. In this article, we are going to take a look at where ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to p ...

John Scarlett; Chairman of the Board, President, Chief Executive Officer; Geron Corp Jim Ziegler; Executive Vice President, Chief Commercial Officer; Geron Corp Joseph Eid; Executive Vice President- ...